AbbVie Inc. (NYSE:ABBV)

The financial trajectory between 2021 and 2025 is characterized by a significant period of value destruction followed by a recent return to positive economic profit. A critical downturn occurred in 2023, driven by a sharp decline in operating performance that outweighed the reduction in the invested capital base.

Net Operating Profit After Taxes (NOPAT)

A severe contraction is observed in 2023, where NOPAT fell from 11,543 million US$ in 2022 to 3,292 million US$. While a recovery trend is evident through 2024 and 2025, reaching 5,919 million US$, the operating profit levels remain substantially lower than those recorded during the 2021-2022 period.

Cost of Capital

A consistent upward trend is noted throughout the five-year period, rising from 7.97% in 2021 to 8.87% in 2025. This steady increase in the required rate of return indicates a rising hurdle for value creation, increasing the cost of maintaining the invested capital base.

Invested Capital

Invested capital underwent a general downward trend, decreasing from 95,922 million US$ in 2021 to 61,356 million US$ in 2025. This reduction suggests a streamlining of the capital base or a divestment phase, although the contraction was not sufficient to maintain positive economic profit during the 2023-2024 period.

Economic Profit

Economic profit shifted from strong positive values in 2021 (4,716 million US$) and 2022 (4,551 million US$) to significant deficits in 2023 (-2,645 million US$) and 2024 (-1,499 million US$). The return to a positive value of 474 million US$ in 2025 indicates that NOPAT has once again exceeded the cost of capital charge, signaling a return to economic value creation.

Net earnings attributable to AbbVie Inc. exhibited an initial increase from 2021 to 2022, followed by a substantial decline in 2023 and a slight recovery in 2024 and 2025. However, the trend in net operating profit after taxes (NOPAT) presents a different pattern. NOPAT decreased from 2021 to 2023, then increased significantly in 2024 and 2025.

NOPAT Trend

NOPAT began at US$12,362 million in 2021, decreasing to US$11,543 million in 2022, representing a decline of approximately 6.7%. A more pronounced decrease occurred in 2023, with NOPAT falling to US$3,292 million. This represents a substantial reduction of over 71% from the 2022 value. A recovery is then observed in 2024, with NOPAT rising to US$4,563 million, and continuing upward in 2025 to reach US$5,919 million. The 2025 value, while representing a significant improvement from 2023, remains below the levels seen in 2021 and 2022.

The divergence between the trends in net earnings and NOPAT suggests potential shifts in the company’s capital structure or non-operating items. While net earnings decreased significantly in 2023, the NOPAT decline was even more substantial, indicating that factors beyond core operating profitability contributed to the reduction in net income. The subsequent recovery in NOPAT, exceeding the recovery in net earnings, suggests improvements in operational efficiency or changes in the cost of capital may be influencing the results.

Relationship between NOPAT and Net Earnings

In 2021 and 2022, NOPAT was consistently higher than net earnings attributable to AbbVie Inc. However, this relationship changed in 2023 and 2024, where net earnings exceeded NOPAT. By 2025, net earnings and NOPAT were relatively close, but net earnings remained slightly higher. This difference could be attributed to items such as interest expense, taxes, and other non-operating income or expenses.

The substantial fluctuations in NOPAT warrant further investigation to understand the underlying drivers. A detailed analysis of the components of NOPAT, including operating revenue, operating expenses, and tax rates, would be necessary to pinpoint the specific factors contributing to these changes.

The reported income tax expense and cash operating taxes exhibit distinct trends over the five-year period. Income tax expense fluctuates considerably, while cash operating taxes generally increase, though with notable variations.

Income Tax Expense

Income tax expense increased from US$1,440 million in 2021 to US$1,632 million in 2022, representing a rise of approximately 13.3%. A subsequent decrease was observed in 2023, with expense falling to US$1,377 million. A significant shift occurred in 2024, resulting in a tax benefit of US$570 million. This was followed by a substantial increase in expense to US$2,364 million in 2025. The volatility suggests potential impacts from changes in tax laws, deferred tax asset adjustments, or significant shifts in pre-tax income.

Cash Operating Taxes

Cash operating taxes demonstrate an overall upward trend, although not consistently. The amount rose from US$2,843 million in 2021 to US$3,997 million in 2022, an increase of approximately 40.6%. Further growth was seen in 2023, reaching US$4,625 million. A considerable decline occurred in 2024, with cash taxes decreasing to US$1,339 million. The final year, 2025, shows a recovery to US$3,414 million. The fluctuations in cash taxes are likely influenced by timing differences between income tax expense and actual cash payments, as well as potential tax planning strategies.

Relationship between Income Tax Expense and Cash Operating Taxes

A divergence is apparent between the two measures. While income tax expense is reported on the income statement based on accounting standards, cash operating taxes reflect the actual cash outflows for taxes. The significant difference in 2024, where an income tax benefit is recorded alongside a cash outflow, indicates substantial deferred tax impacts or tax credits being utilized. The generally higher level of cash taxes compared to income tax expense throughout the period suggests the company may be utilizing tax loss carryforwards or experiencing temporary differences that result in higher cash payments than reported expense.

The observed patterns warrant further investigation into the underlying drivers of these fluctuations, particularly the significant changes in 2024 and 2025, to fully understand their implications for the company’s financial position and future cash flows.

The reported invested capital demonstrates a declining trend over the five-year period. Total reported debt & leases and stockholders’ equity both contribute to the calculation of invested capital, and changes in these components influence the overall trend.

Invested Capital Trend

Invested capital decreased from US$95,922 million in 2021 to US$61,356 million in 2025. The most significant decrease occurred between 2022 and 2023, falling from US$82,134 million to US$68,204 million. A smaller decrease was observed between 2021 and 2022. A slight increase occurred between 2023 and 2024, followed by a further decrease in 2025.

Debt & Leases

Total reported debt & leases decreased from US$77,575 million in 2021 to US$64,191 million in 2022, continuing to US$60,286 million in 2023. An increase to US$68,019 million was noted in 2024, followed by a marginal increase to US$68,379 million in 2025. While fluctuating, the level of debt remained relatively stable between 2024 and 2025.

Stockholders’ Equity

Stockholders’ equity increased from US$15,408 million in 2021 to US$17,254 million in 2022. However, a substantial decline was observed in subsequent years, decreasing to US$10,360 million in 2023, US$3,325 million in 2024, and ultimately reaching a deficit of US$-3,270 million in 2025. This negative equity position in the final year represents a significant shift.

The decrease in invested capital appears to be primarily driven by the substantial reduction in stockholders’ equity, particularly in the later years of the period. While debt levels decreased initially, they stabilized and even increased slightly in the most recent years, suggesting that debt reduction is not the primary driver of the overall decline in invested capital. The transition to negative stockholders’ equity in 2025 is a notable development that warrants further investigation.

The financial performance from 2021 to 2025 is characterized by significant volatility in economic value creation and a consistent reduction in the total invested capital base. A period of value destruction occurred between 2023 and 2024, following a peak in economic efficiency in 2022, before a return to positive economic profit was achieved in 2025.

Economic Spread Ratio

A sharp reversal in the economic spread ratio is observed, moving from a peak of 5.54% in 2022 to a significant low of -3.88% in 2023. This negative spread indicates a period where the return on invested capital fell below the cost of capital. However, a recovery trend is evident in the subsequent years, with the ratio improving to -2.16% in 2024 and returning to positive territory at 0.77% by the end of 2025.

Economic Profit

Economic profit mirrored the trend of the spread ratio, declining from 4,716 million USD in 2021 to a deficit of 2,645 million USD in 2023. The magnitude of the loss narrowed to 1,499 million USD in 2024, eventually pivoting back to a surplus of 474 million USD in 2025. This trajectory suggests a period of significant financial pressure or strategic restructuring followed by a stabilization of returns.

Invested Capital

A sustained downward trend in invested capital is observed throughout the five-year period, decreasing from 95,922 million USD in 2021 to 61,356 million USD in 2025. This represents a substantial contraction of the capital base, which may indicate asset divestitures, write-downs, or a strategic shift toward a more capital-light operational model. The reduction in capital appears to have coincided with the recovery of the economic spread ratio in the final two years of the analysis.

The analysis of economic performance from 2021 to 2025 reveals a period of significant volatility in value creation, characterized by a sharp contraction in economic profit followed by a gradual recovery. While net revenues demonstrated overall resilience and growth, the economic profit margin experienced a severe decline, indicating that the company struggled to generate returns above its cost of capital during the middle of the observed period.

Net Revenue Trajectory

Net revenues exhibited a fluctuating but generally upward trend. Starting at 56,197 million US$ in 2021, revenues peaked in 2022 at 58,054 million US$ before experiencing a contraction to 54,318 million US$ in 2023. A recovery phase followed, with revenues increasing to 56,334 million US$ in 2024 and reaching a period high of 61,160 million US$ by December 31, 2025.

Economic Profit Performance

Economic profit underwent a substantial reversal, transitioning from a positive 4,716 million US$ in 2021 to a significant deficit of -2,645 million US$ in 2023. This downward trend persisted into 2024 with a loss of -1,499 million US$, before returning to positive territory in 2025 with a value of 474 million US$. The magnitude of the 2025 recovery is notably lower than the levels maintained in 2021 and 2022.

Economic Profit Margin Trends

The economic profit margin closely mirrored the volatility of the absolute economic profit. A strong positive margin of 8.39% in 2021 declined to 7.84% in 2022, followed by a precipitous drop to -4.87% in 2023. While the margin improved to -2.66% in 2024 and eventually recovered to 0.77% in 2025, the overall trend indicates a significant compression of value-added returns relative to total revenue over the five-year span.

The divergence between increasing net revenues and declining economic profit margins between 2022 and 2024 suggests that the increase in operational scale did not translate into economic value. The return to a positive margin in 2025 signals a restoration of value creation, although the efficiency of this creation remains substantially lower than the baseline established in 2021.